NOVAVAX Aktie

>NOVAVAX Aktienkurs

6.624 EUR -4.1% (TradegateBSX)

Ask: 6.723 EUR / 1000 Stück

Bid: 6.655 EUR / 1000 Stück

Tagesumsatz: 34923 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

NOVAVAX Aktie über LYNX handeln

Intraday

1 Jahr

>NOVAVAX Performance

1 Woche: -10,5%

1 Monat: -18,4%

3 Monate: +8,3%

6 Monate: -18,0%

1 Jahr: +30,3%

laufendes Jahr: +14,7%

>NOVAVAX Aktie

Name:

NOVAVAX INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6700024010 / A2PKMZ

Symbol/ Ticker:

NVV1 (Frankfurt)

Kürzel:

FRA:NVV1, ETR:NVV1, NVV1:GR

Index:

Webseite:

https://novavax.com/

Profil:

Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialization of recombinant vaccines to protect against serious infectious diseases. It specializes in protein-based vaccine platforms, including its proprie..
>Volltext..

Marktkapitalisierung:

1132.05 Mio. EUR

Unternehmenswert:

733.85 Mio. EUR

Umsatz:

973.29 Mio. EUR

EBITDA:

511.92 Mio. EUR

Nettogewinn:

381.44 Mio. EUR

Gewinn je Aktie:

2.37 EUR

Schulden:

240.88 Mio. EUR

Liquide Mittel:

217.89 Mio. EUR

Operativer Cashflow:

-211.93 Mio. EUR

Bargeldquote:

1.62

Umsatzwachstum:

45.16%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NOVAVAX

Letzte Datenerhebung:

05.04.26

>NOVAVAX Kennzahlen

Aktien/ Unternehmen:

Aktien: 162.94 Mio. St.

Frei handelbar: 95.25%

Leerverk. Aktien: -

Rückkaufquote: 0.37%

Mitarbeiter: 749

Umsatz/Mitarb.: 1.3 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 79.52%

Bewertung:

KGV: 3.26

KGV lG: -

KUV: 1.22

KBV: -

PEG-Ratio: -

EV/EBITDA: 1.43

Rentabilität:

Bruttomarge: 93.5%

Gewinnmarge: 39.19%

Operative Marge: 50.14%

Managementeffizenz:

Gesamtkaprendite: 31.61%

Eigenkaprendite: -

>NOVAVAX Peer Group

Gesundheit, Impfstoffentwicklung/ Impfstoffhersteller, Covid 19- Behandlung/ post Covid/ long Covid

>NOVAVAX Chart & Kurs - Tradegate

>NOVAVAX News

02.04.26 - 01:00	Novavax (NVAX) Stock Dips While Market Gains: Key Facts (Zacks)
	In the closing of the recent trading day, Novavax (NVAX) stood at $8.02, denoting a -1.47% move from the preceding trading day....

30.03.26 - 16:48

3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next (24/7 Wall St.)

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same period, still below its pandemic peak. Novavax (NASDAQ: NVAX) has lost 95.3% in five years. The central question for any investor holding or considering ... 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next The post 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next appeared first on 24/7 Wall St.....

30.03.26 - 16:45	Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know (Zacks)
	Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

30.03.26 - 14:02	Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development (PR Newswire)
	Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant......

27.03.26 - 00:00	Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
	In the most recent trading session, Novavax (NVAX) closed at $8.95, indicating a -4.18% shift from the previous trading day....

21.03.26 - 00:00	Novavax (NVAX) Stock Moves -1.23%: What You Should Know (Zacks)
	Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day....

17.03.26 - 15:45	Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock (Zacks)
	Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock....

11.03.26 - 03:12	Novavax auf Leerink-Konferenz: Strategische Neuausrichtung angekündigt (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.26 - 16:00	Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates (Zacks)
	NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year....

27.02.26 - 09:30	FOMO an der Wall Street: Novavax meldet überraschenden Gewinn – Aktie schießt zweistellig hoch (Wallstreet-Online)
	Ein Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält dieses Momentum?...

26.02.26 - 22:33	Novavax to Participate in Upcoming Investor Conferences (PR Newswire)
	GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference: Fireside Chat Date: Tuesday, March 3, 2026 Time: 2:30 p.m. Eastern Time (ET)......

26.02.26 - 21:12	Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 19:45	Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks)
	Novavax (NVAX) delivered earnings and revenue surprises of +116.60% and +87.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...

26.02.26 - 17:42	Novavax übertrifft im 4. Quartal 2025 die Erwartungen – Aktie legt zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 15:09	Novavax posts Q4 revenue beat and net income for 2025 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 14:33	Earnings Snapshot: Novavax beats Q4 revenue estimates; introduces FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 14:27	Novavax shares subdued despite earnings, revenue beat (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 14:03	Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire)
	Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility......

25.02.26 - 19:12	Preview: Novavax′s Earnings (Benzinga)
	Importance Rank: 1 read more...

25.02.26 - 15:51	Novavax Q4 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram